Thailand PGT CMS

博客

  • Time-Lapse Incubation and AI Embryo Grading: What They Show and Where Their Limits Lie

    Time-lapse incubation and AI embryo grading are laboratory tools for watching and describing embryos. Neither one treats an embryo, repairs it, or confirms that it will implant. What they change is the amount and type of information an embryologist has when deciding which embryo to transfer or freeze — and how that information is recorded and explained.

    If you are reading a Thai clinic’s technology page and trying to work out whether these tools matter for your cycle, the useful question is not “is this advanced?” but “what does it add to the assessment of my embryos, and would it change any decision in my case?” That question belongs with the treating clinician and embryologist; a coordination service can help you put it in writing and get an answer back, but cannot interpret your embryos.

    What time-lapse incubation actually does

    A standard incubator keeps embryos in a controlled environment and an embryologist removes them periodically to look at them under a microscope. A time-lapse system places a camera inside or attached to the incubator and captures images at intervals, so development is recorded continuously rather than at a few snapshots.

    Two practical consequences follow. First, the embryo spends less time outside its controlled environment, because routine observation no longer requires repeated handling. Second, the recording produces a timeline: when each cell divided, how regular the intervals were, whether division looked unusual. This timing information is sometimes called morphokinetic data.

    What time-lapse does not do is choose an embryo for you. It generates a record. Someone — an embryologist, sometimes with software support — still has to interpret that record and decide what it means for this cycle. A camera in an incubator is an observation tool, not a selection device.

    What AI embryo grading is, in plain terms

    AI embryo grading usually means a software model that has been trained on large numbers of embryo images, each linked to some recorded outcome or label, and that then produces a score, ranking or category for a new embryo image. The model has learned patterns that correlated with the labels in its training data.

    That description already contains the main limits. The model can only reflect patterns present in the data it learned from. It produces a number, not an explanation you can inspect. And a correlation in a dataset is not a cause: a high score does not make an embryo implant, and a lower score does not prove an embryo cannot.

    AI grading is best understood as decision support — an additional opinion alongside the embryologist’s conventional assessment. It is not a diagnosis of embryo health, and it is not a prediction of your individual outcome.

    How this relates to conventional morphology grading

    Conventional grading is a trained embryologist looking at an embryo under a microscope and describing what can be seen: cell number, symmetry, fragmentation, the appearance of the outer cell layer and inner cell mass at the blastocyst stage. It is a judgement, made against agreed descriptive criteria, and it is the long-established basis of embryo assessment in IVF laboratories.

    Time-lapse adds timing to that picture. AI adds a computed score. Neither has replaced the embryologist, and no single assessment method is established as superior for live birth. A clinic may use all three together, or only conventional grading, and still be running a careful laboratory.

    Tool What it produces What it does not do
    Conventional morphology grading A descriptive grade from direct microscopic observation Confirm genetic status or guarantee implantation
    Time-lapse imaging A continuous image record and division-timing data Select or improve an embryo on its own
    AI grading software A score or ranking based on learned image patterns Diagnose embryo health or predict your pregnancy

    The limits worth understanding before you compare clinics

    Several limits are worth holding in mind when you read a technology description or a quotation.

    • Training data and validation. A model’s usefulness depends on what it was trained on and whether it was tested on embryos from a different setting. Ask whether the clinic can tell you which system it uses and whether that system has been validated independently of the company that built it.
    • Version and configuration. Software changes. Two clinics using the same product name may be running different versions or settings, so “we use AI grading” is not a like-for-like statement.
    • Opaque scores. If you are shown a number, ask what it is derived from and how the embryologist weighed it. A score you cannot interpret is not information you can use.
    • Correlation is not causation. Embryos that scored well and implanted do not prove the score caused the pregnancy.
    • No guarantee at the top of the scale. A high score does not guarantee implantation, and a lower score does not rule an embryo out. Chromosome findings from a biopsy are a separate question again, and morphology and genetic results can point in different directions — see embryo appearance versus genetic test results.

    It is also worth being clear about what any laboratory tool can say about chromosome number. Time-lapse images and AI scores describe appearance and timing; they do not read an embryo’s chromosomes. PGT-A involves sampling cells from an embryo and has its own limitations, including the possibility of incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA, PGT-A). A reported finding from a sample is not the same as a confirmed description of the whole embryo, which is why mosaic results in particular need careful discussion with the treating clinician and a genetic counsellor (ASRM, 2023).

    Reading a clinic’s technology description

    Technology pages tend to describe equipment. What you need is how the equipment feeds into a decision. A short set of questions, sent before a consultation, usually gets a more concrete answer than asking on the day:

    1. Which time-lapse or AI system do you use, and is it used for every cycle or selected cases?
    2. Who reviews the time-lapse recording, and at what points in the cycle?
    3. Does the AI score appear in the embryology report, and how is it weighted against the embryologist’s own grading?
    4. Has there been a case in which the software and the embryologist disagreed? What happened?
    5. Would using or not using this tool change any decision in my cycle — for example, which embryo is transferred first, or whether to culture to blastocyst?
    6. Is there an additional cost, and is it included in the quotation you have given me?

    The last two are the ones patients most often forget. A tool that does not change a decision in your cycle may still be worth having for the record, but you should know that before you agree to it. The role of the embryologist in a Thai laboratory, and how to ask about it, is covered in understanding the role of the embryologist.

    Getting the assessment in writing

    Embryo assessment is easiest to discuss when you have the actual record. Before treatment, ask what the embryology report will contain: the grade given to each embryo, whether time-lapse or AI outputs are included, the date and stage at each assessment, and who signed it. If you are comparing quotations, check whether time-lapse culture or AI grading is listed as an inclusion or an add-on, so that two quotes are compared on the same basis.

    If you are reviewing several clinics before deciding, the countrywide shortlist at Thailand IVF hospital and clinic comparison is a starting point for that research; it is an editorial comparison, not a statement that one laboratory’s assessment method produces better outcomes.

    After you return home, the embryology report and any laboratory notes become part of your records. If you need them sent to a clinician in your own country, or want follow-up questions put to the clinic, that handover is a communication task: agree the recipient, the method and what exactly is being requested. A coordination service can organise the request and track outstanding documents; it cannot interpret the report or advise on treatment. Questions about what your embryos’ grades mean for your own chances belong with the treating clinician and embryologist, who can see the full record.

    A realistic way to hold all this

    Time-lapse incubation and AI embryo grading are genuine laboratory tools that can add information and reduce handling. They sit alongside, not above, the embryologist’s judgement, and none of these methods is established as superior for live birth. Treat a technology description as a prompt for questions rather than a promise, ask what would change in your own cycle, and keep the written record. That is a more useful basis for a decision than the equipment list alone.

    Frequently asked questions

    Does time-lapse incubation improve embryo quality?

    Time-lapse imaging records development and reduces how often embryos are handled for observation. It does not itself improve an embryo or select one; the interpretation and decision still rest with the embryologist and treating clinician.

    If an AI system gives my embryo a high score, does that mean it will implant?

    No. AI grading produces a score based on patterns in the data it was trained on. A high score does not guarantee implantation, and a lower score does not rule an embryo out. Ask the embryologist how the score was weighed in your cycle.

  • IMSI and Abnormal Sperm Morphology: What to Ask Before You Agree

    If a semen analysis reports abnormal sperm morphology, IMSI (intracytoplasmic morphologic sperm injection) often comes up as an option. It is a variant of ICSI in which the embryologist selects sperm at very high magnification before injecting a single sperm into an egg. The practical question is not whether IMSI sounds more precise, but whether it adds anything for your particular case, and what you should confirm before paying for it.

    The short answer: abnormal morphology alone is not a clear reason to choose IMSI. The evidence reviewed by the UK fertility regulator, the HFEA, is not strong enough to show that IMSI improves the chance of having a baby compared with standard ICSI, including in male-factor infertility, and that review did not support using IMSI over standard ICSI. That does not make IMSI forbidden or pointless in every situation, but it does mean the decision should rest on a specific clinical reason and an honest conversation about uncertainty, not on the promise of a better result.

    What IMSI actually changes

    Standard ICSI already involves choosing a sperm to inject. IMSI changes the magnification used for that choice: the HFEA describes IMSI as selecting sperm for ICSI using microscopy above 6000x magnification. The idea is that a more detailed view of sperm shape might help the embryologist avoid sperm with subtle abnormalities.

    Two things follow from this. First, IMSI is not a different fertility treatment in the way that, say, a frozen versus fresh transfer is; it is a laboratory selection step layered onto ICSI. Second, the benefit, if any, would come from better sperm selection, so the relevant questions are about what is being selected, how, and whether that selection has been shown to matter for outcomes.

    If you are still deciding between ICSI and conventional insemination, a separate comparison of ICSI versus standard IVF is a more useful starting point than IMSI, because IMSI only becomes relevant once ICSI is already on the table.

    What the evidence does and does not show

    It is worth being precise about the strength of the evidence, because clinics sometimes present IMSI as an upgrade without saying how uncertain the benefit is.

    • What is established: IMSI is a high-magnification method of selecting sperm for ICSI.
    • What is not established: that IMSI improves the chance of a live birth compared with standard ICSI, including for couples whose infertility is attributed to the male partner.
    • What the regulator concluded: the reviewed evidence did not support using IMSI over standard ICSI.

    This matters for how you read a clinic’s enthusiasm. A clinic may offer IMSI because it has the equipment and believes in the approach, which is not the same as having evidence that it works better for you. When someone recommends IMSI for abnormal morphology, a fair question is: what specific evidence or local experience supports that recommendation in my case, and what would happen if we used standard ICSI instead?

    Morphology is also only one part of a semen analysis. Sperm count, movement and shape are usually read together, and a single abnormal morphology figure can be misleading if it is looked at in isolation. The guide to reading a semen analysis as one picture explains why the whole result, and how it was measured, matters.

    Clinical indication: questions for your clinician

    These are questions for a licensed clinician who has your records, not something a coordination service can answer. Ask them directly, and ask for the reasoning rather than only the recommendation.

    1. Does my morphology result, on its own, justify IMSI? If the answer is yes, ask what threshold or finding is driving that, and whether the same conclusion would apply if my other semen parameters were different.
    2. Would standard ICSI be a reasonable alternative in my case? If so, what would we lose by choosing it?
    3. Does a history of poor fertilisation or previous cycle failure change the recommendation? Prior outcomes can matter clinically, so ask whether they do here and why.
    4. Does sperm DNA fragmentation testing change the picture? If fragmentation has been measured or is being considered, ask how, if at all, it would affect the choice between IMSI and standard ICSI. Do not assume a high result automatically points to IMSI.
    5. What are this clinic’s own outcomes with IMSI compared with standard ICSI? Ask what they measure, over what period, and whether the numbers are audited. Treat any figure as context for a conversation, not a prediction for you.
    6. What are the risks and limits? Ask about anything that could go wrong or be wasted, including cycles where no suitable sperm are found or where the selection step does not change the outcome.

    If you are weighing IMSI against another add-on such as MACS, the comparison of MACS versus IMSI sperm selection sets out the decision criteria side by side. Neither should be treated as proven superior.

    Laboratory questions: who does it and how is it recorded

    IMSI depends on equipment and on the embryologist using it. Because the technique is only as good as its execution, ask about the laboratory rather than only the clinic’s brand.

    • Is IMSI performed in-house, or is any part of the process outsourced? If outsourced, where and by whom?
    • Who performs the selection, and how much experience do they have with high-magnification ICSI?
    • How is the selection documented in the lab record, and will that record be available to you or a future clinic?
    • What happens if the sample on the day does not yield sperm that meet the selection criteria?
    • Does using IMSI change the timing of the cycle, the embryology schedule, or how embryos are assessed afterwards?

    These are practical questions a coordinator can help you put in writing and send to the hospital, but the answers must come from the clinical and laboratory team.

    Cost, quotes and planning

    IMSI is usually charged as an addition to ICSI, so the useful exercise is comparing what each quote includes, not just the headline number. Ask for the incremental fee for IMSI, and whether it is charged per cycle, per attempt, or only when the selection is actually performed.

    Then check the surrounding items, because a lower IMSI fee can sit inside a quote that excludes something you will need:

    • Is standard ICSI included, and is IMSI listed separately?
    • Are embryology, laboratory and monitoring fees itemised?
    • If PGT is being planned, does IMSI change the embryo-selection plan, the biopsy timing or the PGT quote? Ask the clinician and the laboratory, since this is a clinical and laboratory question, not a billing one.
    • What is refundable or transferable if the cycle is cancelled or the selection step is not used?
    • Are there charges for records, reports or follow-up communication after you return home?

    Mark every field the hospital has not confirmed. A quote with clear gaps is more useful than one that looks complete but leaves the inclusions vague.

    A worked planning sequence

    Suppose your semen analysis shows abnormal morphology and you are researching clinics in Thailand. A practical order of work looks like this:

    1. Collect the records. Gather the full semen analysis reports, any repeat tests, and any prior cycle summaries, with dates. Note which laboratory produced each result and whether the same method was used.
    2. Write the clinical questions first. Use the list above, adapted to your history, and send them before any consultation so the clinician can review the records.
    3. Ask for a remote consultation. Request the format, the records the clinic wants in advance, the time zone, and whether a fee applies. Confirm these in writing.
    4. Request itemised quotes from more than one clinic. Compare the same inclusions across quotes, and keep a column for unconfirmed items.
    5. Plan the Thailand arrangements only after the clinical plan is clear. Appointment location, travel dependencies and language support should follow a confirmed plan, not precede it.
    6. Agree the return-home handoff. Before you travel, decide who will receive your records, in what format, and which follow-up questions you want answered after the cycle.

    If you are at an earlier stage and want the broader picture of male-factor diagnosis and options, the guide to male factor infertility in Thailand covers the diagnostic pathway, and the questions to ask before planning are collected in male factor infertility and PGT planning questions.

    Where coordination helps, and where it stops

    A coordination service can help you organise records, draft and send questions, request appointments and remote consultations, plan travel around confirmed appointments, and arrange a records handover after you return home. It cannot tell you whether IMSI is clinically indicated for you, interpret your semen analysis, or predict your chances. Those answers belong to licensed clinicians, and the decision about whether to add IMSI should be made with them, with the uncertainty in the evidence stated plainly.

    If you would like help preparing a question list and comparing what each quote includes, you can request a case review and we will set out what is confirmed and what still needs a clinical answer.

    Frequently asked questions

    Does abnormal sperm morphology mean I need IMSI?

    Not automatically. Abnormal morphology is one finding among several in a semen analysis, and the reviewed evidence does not show that IMSI improves the chance of a baby compared with standard ICSI, including in male-factor infertility. Ask your clinician whether there is a specific reason in your history that would justify IMSI, and what standard ICSI would mean for you.

    Is IMSI the same as ICSI?

    No. ICSI is the injection of a single sperm into an egg. IMSI is a way of selecting that sperm using microscopy above 6000x magnification before injection, so it is a laboratory selection step added to ICSI rather than a separate treatment.

  • Thailand IVF Stimulation Phase: Cycle Schedule and Preparation Guide

    Stimulation is the part of an IVF cycle where medication is used to encourage several follicles to grow, and it is usually the phase that decides when you need to be in Thailand. The exact calendar is set by your treating clinic for your own cycle, but the general shape is predictable enough to plan around: preparation and baseline checks first, a start date tied to your menstrual cycle, a series of injection days with monitoring every few days, then a trigger injection timed to egg retrieval.

    This guide is written for someone planning a first cycle from abroad. It explains how the phase is sequenced, what to prepare before travel, and which decisions belong to you, your clinic and any coordination support you use. It does not tell you which protocol or dose is right for you — that is a clinical decision made with your doctor after reviewing your history.

    How the stimulation phase is sequenced

    Stimulation rarely begins on the day you first contact a clinic. It sits at the end of a short run-up that usually includes a baseline assessment and, depending on your protocol, some form of cycle synchronisation or priming beforehand.

    Before stimulation: baseline assessment

    A baseline assessment typically involves a review of your history, blood tests and a pelvic ultrasound, and it is used to confirm that starting stimulation is appropriate for this cycle. Your clinic will tell you which tests it wants, whether they can be done at home or need to be repeated in Thailand, and how recent they must be. Test validity windows vary between clinics and are not something to assume — ask directly and get the answer in writing.

    Cycle synchronisation and priming

    Some protocols include a step before stimulation itself, such as medication or timing instructions intended to align your cycle with the clinic’s schedule. Whether this applies to you, what it involves and when it starts are clinical decisions. What matters for planning is that this step can shift your start date, so it is worth confirming early whether your protocol includes one.

    What the stimulation days usually look like

    Once stimulation starts, the phase is built around two parallel tracks: daily medication at home or in your accommodation, and monitoring visits at the clinic.

    • Start date. Stimulation usually begins on a specific day of your menstrual cycle, as instructed by your clinic. The clinic, not a general guide, confirms the date for your cycle.
    • Daily injections. Medication is typically given as daily injections for a number of days. Your clinic provides the prescription, the technique teaching and the instructions on timing and storage.
    • Monitoring every few days. Blood tests and ultrasound are used to track follicle growth and hormone levels, and the results inform whether your dose stays the same or is adjusted.
    • A moving end date. The number of stimulation days is not fixed in advance for most people. It depends on how your follicles respond, which is why the retrieval date is confirmed as the cycle progresses rather than booked firmly at the start.

    Because the end date can move, treat any retrieval date given early in planning as provisional. Build flexibility into flights and accommodation rather than assuming a fixed day count.

    Trigger timing and the link to egg retrieval

    When monitoring shows the follicles are ready, the clinic schedules a final “trigger” injection. The trigger is timed precisely, and egg retrieval is then planned for a set interval after it — commonly described as roughly 36 hours, though your clinic will give you the exact time for your cycle. Two practical consequences follow:

    • The trigger time is not flexible. If you are managing your own injections, confirm the exact clock time, the time zone you are working in, and what to do if you are unsure.
    • You need to be physically in Thailand, with travel to the clinic arranged, before the trigger. This is the point where travel planning and the clinical schedule have to meet.

    For a detailed walk-through of what happens on retrieval day and immediately after, see the day-by-day egg retrieval guide for international patients.

    Pre-stimulation preparation checklist

    Most of the preparation work happens before you travel. The items below are the ones patients most often need to organise; your clinic will confirm which apply to you.

    Records and test results

    • A dated list of the tests your clinic has requested, with the date each was done and the result attached.
    • Any previous cycle records, operation notes or relevant history your doctor has asked for.
    • Confirmation of which results the clinic has actually received and reviewed, not just sent.
    • Clarity on whether any test needs repeating in Thailand and whether that affects your arrival date.

    If you want a fuller picture of what diagnostic preparation can involve, the guide to IVF diagnostic preparation in Thailand covers the categories clinics commonly ask about.

    Medication plan

    There are two broad approaches: bringing prescribed medication with you, or having it prescribed and obtained in Thailand. Each has practical implications — customs and transport rules for medicines, storage and refrigeration during travel, prescription documentation, and cost. Your clinic decides what it will prescribe and how it prefers to supply it; ask which approach it recommends for your protocol and what documentation it will provide. Do not change, stop or start any medication without your prescriber’s instruction.

    Questions to settle with the clinic before booking

    • What is my confirmed start date, and what could move it?
    • Which baseline tests do you need, by when, and where can they be done?
    • How often should I expect monitoring, and can any early monitoring be done locally under your plan?
    • Where will I be given injection teaching, and who do I contact if I am unsure about a dose or timing?
    • What is the latest date I can arrive and still follow the plan?
    • How and when will you send the personalised calendar, and who updates it if monitoring changes the plan?

    These are clinical and scheduling questions, and your treating team is the right source for the answers. A coordinator can help you organise the questions, request the documents and keep track of what has been confirmed.

    Travel timing for the stimulation phase

    The central travel decision is when to arrive relative to your first monitoring appointment. Arriving with a small buffer before the first clinic visit is a common approach, because it allows for flight disruption and for any baseline check that has to happen in person. The right buffer for you depends on your protocol and the clinic’s instructions.

    Practical points to plan around:

    • Flexible bookings. Choose flights and accommodation that can be changed, since the retrieval date may shift as monitoring progresses.
    • Local monitoring. Some clinics allow early monitoring scans at a local clinic under their plan, with results sent ahead. Ask whether this is possible for you, what the clinic needs from the local provider, and whether it changes your arrival date.
    • Length of stay. Your stay needs to cover from before the first monitoring visit through retrieval and the immediate aftercare your clinic advises. The guide to how many days you may need in Thailand for an IVF cycle helps you build that estimate.
    • Work and home commitments. Because the end date moves, plan the weeks after retrieval loosely until the clinic confirms timing.

    For a wider view of how arrival, monitoring and retrieval fit into a trip, the IVF travel timeline guide sets the stimulation phase alongside the rest of the journey.

    A worked planning example

    Consider a patient who has been asked for baseline blood tests and a scan, and whose clinic has said stimulation will start on a set day of her cycle. A workable plan might look like this:

    1. Complete the requested tests at home and send the dated results ahead, asking the clinic to confirm receipt and whether anything needs repeating.
    2. Ask the clinic to confirm the start date, the monitoring cadence and whether any early scan can be done locally.
    3. Book changeable flights to arrive a few days before the first in-person monitoring visit, and accommodation that can be extended.
    4. Confirm the medication plan — what will be prescribed, where it will be obtained, and what documentation you will carry.
    5. Keep the days around the expected retrieval flexible until monitoring confirms the trigger date.
    6. Before returning home, ask what records you will need and who to contact with follow-up questions.

    This is a planning illustration, not a template for a clinical protocol. Your clinic’s calendar replaces it once your cycle is confirmed.

    Who confirms what

    The division of responsibility is worth stating plainly. Your treating clinic confirms your personalised calendar, monitoring schedule, medication instructions, trigger timing and retrieval plan, and its clinicians answer your questions about diagnosis, options, risks and your individual chances. Coordination support sits alongside that: organising records and outstanding document requests, requesting appointments or remote consultations, helping with travel-stage and language needs around confirmed appointments, and assisting with records handover and follow-up questions after you return home. Coordination does not diagnose, prescribe or guarantee appointment availability, and third-party booking costs need separate confirmation.

    If you would like help preparing your questions and comparing what different clinics include in their written plans, you can request a case review. For background on how medication protocols and schedules are structured, see the guide to how IVF drug protocols and schedules work.

    Frequently asked questions

    Can I start stimulation before I arrive in Thailand?

    Some clinics allow part of the stimulation phase to begin at home, with early monitoring done locally and results sent ahead, while others ask you to be in Thailand from the start. This depends on your protocol and the clinic's preference, so confirm it before booking travel. If local monitoring is allowed, ask exactly what the clinic needs from the local provider and by when.

    How much notice will I get of my egg retrieval date?

    The retrieval date is confirmed as monitoring shows your follicles are responding, so it is usually settled only a short time before the trigger injection. Treat any earlier date as provisional and keep flights and accommodation changeable until the clinic confirms the trigger timing.

  • IMSI or Standard ICSI? Which Sperm Problems Make the Choice Worth Discussing

    If you are preparing for IVF in Thailand with a male-factor diagnosis, you may have seen IMSI listed as an optional laboratory step alongside standard ICSI. The names look similar and the two are often described together, which makes it hard to tell whether IMSI is a different treatment, a refinement of ICSI, or simply a marketing label. This guide sets out what actually changes, which sperm findings make the question worth raising, and where the evidence stops.

    The short answer

    IMSI (intracytoplasmic morphologic sperm injection) is a way of choosing which sperm to inject. It uses very high magnification microscopy — above 6000x according to the UK regulator’s patient guidance — to inspect sperm shape in more detail before a single sperm is selected for ICSI. The injection step itself is standard ICSI. So IMSI does not change how fertilisation is attempted, and it does not change whether embryos are tested.

    That distinction matters for your decision. IMSI is best understood as a sperm-selection add-on that a clinician may consider for particular male-factor pictures, not as a separate fertility treatment with its own success profile. The same HFEA guidance reports that the reviewed evidence is not strong enough to say whether IMSI improves the chance of having a baby, including in male-factor infertility, and that the evidence reviewed does not support using IMSI over standard ICSI. In other words, the case for IMSI rests on laboratory reasoning and clinical judgement, not on established improvement in live birth.

    What IMSI changes, and what it does not

    Standard ICSI selects a sperm under ordinary laboratory magnification and injects it into an egg. IMSI adds a higher-magnification inspection step before that selection. Everything downstream — fertilisation, embryo development, any planned genetic testing of embryos, transfer — follows the same path.

    • Changes: the magnification and criteria used when a sperm is chosen.
    • Does not change: the injection technique, the number of eggs retrieved, the fertilisation method, embryo testing, or the underlying cause of the male-factor diagnosis.
    • Does not fix: a sperm production problem, a genetic cause, or DNA damage inside the sperm head. Selecting a sperm that looks better under high magnification is not the same as proving that sperm is functionally better.

    This is why the honest framing is “selection refinement with uncertain benefit” rather than “upgrade”. If a clinic presents IMSI as a way to improve embryo quality or guarantee a healthier pregnancy, that claim goes beyond what the published evidence supports.

    Which sperm problems make IMSI worth discussing

    There is no single sperm result that automatically makes IMSI the right choice. The situations below are the ones where clinicians most often raise the question, because each involves either very few normally shaped sperm to choose from or a history that standard ICSI has not resolved. Treat this as a map of the conversation, not a list of indications that apply to you.

    Predominantly abnormal morphology (teratozoospermia)

    When most sperm in a sample have abnormal shape, the pool of normally formed sperm available for selection is small. The logic behind IMSI is that higher magnification may help the embryologist identify the better-formed sperm within that limited pool. Whether that translates into a better outcome is exactly what the evidence has not settled. If your report describes severe teratozoospermia, this is a reasonable point to ask your clinician how they would weigh IMSI against standard ICSI for your sample.

    Severe oligozoospermia with few motile, normally formed sperm

    Where sperm concentration is very low, the practical constraint is the number of usable sperm, not the magnification used to inspect them. IMSI cannot create more sperm. It may be discussed when there are still enough motile, normally formed sperm to make a selection step meaningful, but in very severe cases the limiting factor is the sample itself. Ask directly whether your sample gives the laboratory a realistic choice to make.

    High sperm DNA fragmentation

    Sperm DNA fragmentation is a separate measure from shape and is usually assessed with a dedicated test rather than routine semen analysis. It is often raised in discussions about IMSI because the hope is that better-looking sperm also carry less DNA damage. That link is not established by the evidence summarised here, and a high fragmentation result does not by itself make IMSI the answer. It is a finding to discuss with your clinician, including whether any underlying cause should be addressed first.

    Repeated ICSI fertilisation or implantation failure

    When previous ICSI cycles have produced poor fertilisation or repeated implantation failure without a clear explanation, couples often look for something to change in the laboratory. IMSI is sometimes raised in that situation. Be aware that “we changed the sperm selection method” is not evidence that the change caused a different outcome, and a history of failed cycles usually deserves a broader review — the stimulation protocol, the embryology record, the uterine assessment and any genetic testing already done — rather than a single add-on.

    Surgically retrieved sperm

    When sperm are retrieved surgically, the numbers available are often limited and the sample may contain fewer motile, normally formed sperm. This is a setting where the selection step can feel especially consequential, and where clinicians may discuss IMSI. Whether it helps is again a judgement call rather than an established benefit, and the practical question is whether the retrieved sample offers enough to select from.

    Where IMSI adds little over standard ICSI

    For many male-factor cases, standard ICSI already addresses the core problem: getting a sperm into the egg when sperm numbers, movement or shape make natural fertilisation unlikely. If your semen analysis shows mild abnormalities, or if the male factor is not the main reason for IVF, there is little laboratory rationale for adding a high-magnification selection step, and the evidence does not support routine use over standard ICSI. The same applies when the limiting factor is egg number or embryo development rather than sperm selection.

    A useful way to think about it: IMSI is a question about the choice of sperm, so it only becomes interesting when that choice is genuinely constrained or when previous cycles suggest the standard approach has not worked.

    A comparison you can take to a consultation

    The table below sets out the decision criteria side by side. It is a framework for your discussion, not a recommendation for either option.

    Criterion Standard ICSI IMSI
    What it is Injection of a selected sperm into an egg Standard ICSI with a higher-magnification sperm-selection step beforehand
    Main male-factor situations discussed Broad range of sperm problems where natural fertilisation is unlikely Severe morphology problems, very low usable sperm numbers, high DNA fragmentation, repeated ICSI failure, surgically retrieved sperm
    Evidence for improved live birth Established as a treatment route for male-factor infertility Not established; reviewed evidence does not support IMSI over standard ICSI
    What it cannot change The underlying cause of the male factor The underlying cause, the injection method, or embryo testing decisions
    Practical questions Is ICSI appropriate for our diagnosis? Does this laboratory perform IMSI, how often, and is it included or charged separately?

    How IMSI interacts with planned PGT

    If you are also considering preimplantation genetic testing, keep the two decisions separate. PGT examines embryos — for chromosome number (PGT-A), a known monogenic condition (PGT-M) or a structural rearrangement (PGT-SR) — after fertilisation and development. IMSI acts earlier, at sperm selection. Neither replaces the other, and choosing IMSI does not make PGT more or less appropriate, nor does planning PGT make IMSI necessary.

    What can connect them is the reason for testing. If PGT is being considered because of a known genetic cause in the family, that is a separate clinical pathway from sperm selection. If it is being considered after repeated loss or failed cycles, the same broader review applies. It is worth asking your clinician to explain, in one conversation, what each test or step is meant to answer — and what it would not tell you. Our guide to PGT for male factor infertility covers where testing helps and where it does not.

    What the evidence can and cannot settle

    The most useful thing you can bring to this decision is a clear sense of what is known. The HFEA’s assessment of IMSI is a good benchmark: it describes the technique, reports insufficient moderate- or high-quality evidence to rate whether IMSI improves the chance of having a baby, and states that the reviewed evidence does not support using IMSI over standard ICSI. That does not mean IMSI is harmful or forbidden; it means the benefit is unproven, so the decision belongs with a clinician who can weigh your specific sample, history and laboratory.

    Be cautious with any source — including a clinic’s own material — that presents IMSI as proven to improve success rates, embryo quality or child health. Those claims are not supported by the evidence summarised here. Equally, a clinic that offers IMSI is not doing anything wrong; it is offering an add-on whose value is debated.

    Questions to bring to your clinician

    These are clinical questions, and your treating clinician is the right person to answer them. A coordinator can help you organise the questions and the records, but cannot diagnose or advise on treatment.

    1. Looking at my semen analysis and history, is there a specific reason to consider IMSI, or would standard ICSI be the default?
    2. Does this laboratory perform IMSI in-house, and how often does it carry out the procedure?
    3. Is IMSI included in the quoted cycle cost or charged as a separate add-on? What exactly does the quote cover?
    4. What would you expect IMSI to change in our case, and what would it not change?
    5. If we are planning PGT, does the IMSI decision affect the testing plan in any way?
    6. If a previous ICSI cycle did not work, what else should be reviewed before adding a laboratory step?

    If you are still at the stage of gathering records, our guide to male-factor fertility records to prepare before IVF lists the documents that make these conversations more productive. For the wider picture of what IVF involves with a male-factor diagnosis, see IVF for male factor infertility in Thailand.

    Practical preparation before you decide

    IMSI is usually decided close to the laboratory stage, but the groundwork happens earlier. Three things make the conversation easier:

    • A current, complete semen analysis with the parameters your clinician will actually use, plus any DNA fragmentation result if one has been done.
    • A clear cycle history — how many previous ICSI cycles, fertilisation rates, embryo development and transfer outcomes — if you have had treatment before.
    • A written cost comparison that separates the standard cycle from optional laboratory add-ons, so you can see what IMSI would add and whether it is bundled.

    If you would like help pulling these together, or want your questions and records organised before a remote consultation with a Thai hospital, you can request a case review. The coordination service can help with records, appointment requests and language needs; the clinical judgement about IMSI stays with your treating clinician.

    Frequently asked questions

    Does IMSI improve the chance of a baby compared with standard ICSI?

    The published evidence does not establish that it does. The HFEA reports insufficient moderate- or high-quality evidence to rate whether IMSI improves the chance of having a baby, including in male-factor infertility, and states that the reviewed evidence does not support using IMSI over standard ICSI. A clinician may still consider it for a specific case, but that is a judgement call rather than a proven benefit.

    If I have high sperm DNA fragmentation, should I choose IMSI?

    That is a clinical question for your treating clinician. High DNA fragmentation is one of the findings often discussed alongside IMSI, but the evidence summarised here does not establish that IMSI corrects DNA damage or improves outcomes. It is worth asking whether an underlying cause should be reviewed first and what the clinician expects IMSI to change in your case.

  • Specialist Fertility Hospital vs General Hospital Reproductive Department: How to Choose

    Patients researching fertility care in Thailand often meet two very different kinds of provider under similar-sounding labels. One is a dedicated fertility setting — a specialist reproductive hospital or clinic built around fertility treatment. The other is the reproductive medicine or obstetrics-and-gynecology department inside a general hospital, where fertility care sits alongside many other specialties.

    Neither model is universally better. The useful question is which one fits your medical profile, your coordination needs and the way you want decisions and records handled across a treatment cycle that may span two countries. This guide sets out consistent criteria so you can compare the two settings on the same terms rather than on reputation alone.

    Start with what actually differs

    The two settings differ less in the existence of fertility treatment than in focus and structure.

    A specialist fertility setting concentrates its clinical work, laboratory and staff around reproductive medicine. Consultations, monitoring scans, procedures and embryo laboratory work tend to sit within one fertility-focused team, and the patient pathway is usually designed around fertility treatment from the first visit.

    A general hospital reproductive department offers fertility assessment and treatment within a larger hospital. The fertility team may be a centre or unit inside the hospital, sharing infrastructure with gynecology, surgery, imaging, internal medicine and emergency services. The fertility pathway is one service line among many.

    That structural difference drives most of the practical trade-offs below. It does not tell you which setting will give you a better clinical result, and no public directory can answer that for an individual patient.

    A comparison framework you can apply to any provider

    Use the same criteria for every provider you shortlist, and record answers in writing. The table below shows what to compare and why it matters; the right-hand column is deliberately left for the provider’s own answer.

    Criterion What to compare Why it matters for you
    Scope of fertility services Which diagnostics, IUI, IVF/ICSI, embryo testing pathways, fertility surgery, freezing and counselling are offered on site Services listed publicly may be branch-specific or require confirmation of current testing scope
    On-site multidisciplinary care Whether other specialties you personally need (for example endocrinology, hematology, cardiology or surgery) are available in the same hospital Relevant mainly if you have non-fertility conditions that need coordinated input
    Who owns the cycle The named treating clinician, who reviews monitoring results, and who makes day-to-day decisions Continuity affects how questions and changes are handled during a cycle
    Coordination for international patients Who answers non-clinical questions, how appointments and remote consultations are arranged, and in which language You may be managing much of the cycle from abroad
    Quotation structure Whether the quote is itemised by department and visit or presented as a package, and what is excluded Two quotes can look similar in total while covering different things
    Records and handover How records are shared before arrival and after you return home Your home clinic will need a clear summary to continue care

    Scope of services: read the list carefully

    Public service lists are a starting point, not a guarantee. Some hospital centres describe a pathway — for example, a PGT-A pathway — without stating whether testing is performed on site or referred. Others note that a service is available at some branches but should be confirmed for the branch you are considering. When a provider lists a service you need, ask whether it is available at the location and time you plan to travel, and who performs it.

    If your situation involves embryo testing, it helps to understand what the tests can and cannot show before comparing providers. PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations and can produce incorrect findings; whether to use it should be discussed for your individual situation (HFEA: PGT-A). PGT-M and PGT-SR address different questions — a known monogenic condition and chromosomal structural rearrangements respectively — and a treating team and genetic counsellor should discuss the relevant history, test design and suitability (HFEA: PGT-M and PGT-SR). These are clinical conversations with licensed clinicians; a coordinator can help you put the questions in writing but does not interpret results or advise on testing.

    Team structure and continuity

    In a fertility-focused setting, the same small team often follows a patient from first consultation through monitoring and transfer. In a general hospital department, you may see the fertility clinician for treatment decisions while other departments handle related investigations. Neither arrangement is inherently more continuous — what matters is whether you can name the clinician responsible for your cycle and know who reviews results when your own doctor is unavailable.

    Ask directly: who will review my monitoring scans, who decides on any change to the plan, and how quickly are non-urgent questions answered? For international patients, also ask whether a remote consultation is possible before travel and what format it takes.

    Coordination and communication pathways

    This is where the two settings can feel most different in practice. A dedicated fertility provider may have a single international-patient contact for appointments, quotations and records. A general hospital may route different requests through different departments — fertility centre, international office, billing, medical records. That is not a disadvantage by itself, but you should know the route before you need it.

    Write down, for each provider: the first point of contact, the person or office that answers billing questions, the channel for urgent clinical concerns during a cycle, and the language in which each of these is handled. If you use a coordination service, agree in advance what it will and will not do. Thailand PGT, for example, can help organise your goals and questions, assist with records and communication, coordinate appointment and remote-consultation requests, support travel-stage planning and language needs, and help request records and follow-up communication after you return home. Clinical decisions, result interpretation and prescriptions remain with the treating clinicians, and appointment availability is always subject to hospital confirmation.

    Cost and quotation structure

    Dedicated fertility providers sometimes present treatment as a package, while general hospitals more often bill item by item across departments. Neither format is automatically clearer. What matters is whether the quotation states its inclusions, exclusions and validity, and whether it separates clinician fees, laboratory work, medication, testing and any third-party charges.

    Do not compare headline totals. Compare what each quote covers for the same planned steps, and mark every unconfirmed field — medication doses, number of monitoring visits, whether a procedure is included — as a question rather than an assumption. If a package is offered, ask what happens to the price if your plan changes mid-cycle.

    Weight the criteria by your own medical profile

    The same framework produces different answers depending on your history.

    • If you have significant non-fertility conditions — for example a cardiac, endocrine, hematological or surgical history that needs coordinated input — the availability of relevant specialties in the same hospital, and a clear plan for how they communicate with the fertility team, may deserve more weight. Ask how joint review would work and who coordinates it.
    • If your fertility needs appear uncomplicated and your main concerns are convenience, continuity and clear communication, the focus and single-team structure of a specialist setting may suit you, provided its scope covers what your clinician recommends.
    • If you are travelling from abroad, coordination and records handling may matter as much as clinical scope. A provider that answers non-clinical questions promptly and shares records in a usable format can make a two-country cycle easier to manage.
    • If you need a service such as surgical sperm retrieval or fertility preservation, confirm that the specific service is available at the location you are considering rather than assuming it from a general list.

    These are planning considerations, not eligibility rules. Which setting is clinically appropriate for you is a question for licensed clinicians who have reviewed your history.

    Questions to send each type of provider

    Adapt these to your situation and send them before booking. Keep the answers in one document so you can compare like with like.

    To a specialist fertility hospital or clinic

    • Which services in your public list are performed on site, and which are referred elsewhere?
    • If I need input from another specialty, how is that arranged and who coordinates it?
    • Who will be my named treating clinician, and who covers when they are unavailable?
    • What does your quotation include and exclude, and how long is it valid?
    • Can we hold an initial remote consultation, and what records should I send beforehand?
    • What records will I receive at the end of treatment for my home clinic?

    To a general hospital reproductive department

    • Is fertility care delivered by a dedicated unit within the hospital, and who leads it?
    • Which related specialties can be involved in my care in the same hospital, and how do they share information with the fertility team?
    • How is billing organised across departments, and can I receive one itemised quotation?
    • Who is my contact for non-clinical questions, and in which language?
    • What is the process for urgent concerns during a cycle, including outside office hours?
    • How are records transferred to my home clinic after I leave Thailand?

    What to request in writing

    Before you commit, ask for a short written summary covering: the quotation with inclusions, exclusions and validity; the name of the treating clinician and who covers for them; the records you must send and how they will be transferred; the format and fee of any remote consultation; and the handover process for your home clinic. A provider that cannot confirm a detail in writing is telling you something useful about its coordination — note it as an open question rather than filling the gap yourself.

    If you are still at the research stage and want to see how several providers in the capital compare on these criteria, our Bangkok IVF hospital and clinic comparison guide is a neutral starting point for shortlist research; it is an editorial comparison, not evidence that any provider gives better outcomes. For the broader clinic-versus-hospital question, see how to choose between a clinic and a hospital for IVF in Thailand, and for the practicalities of moving care between settings, choosing between a fertility clinic and a hospital for embryo transfer.

    A short decision checklist

    1. List the services your clinician has discussed with you, and confirm each is available at the location you are considering.
    2. Note any non-fertility conditions that need coordinated input, and ask how each setting would handle them.
    3. Identify the named treating clinician and the cover arrangement.
    4. Map the communication route: first contact, billing, urgent concerns, language.
    5. Request itemised quotations and compare inclusions, not totals.
    6. Confirm the remote consultation format and the records you must send.
    7. Agree the return-home handover: which records, to whom, by what method.
    8. Mark every unanswered item as an open question and follow up before booking.

    Choosing between the two settings is less about finding the single best hospital and more about matching structure to your needs. A specialist fertility hospital and a general hospital reproductive department can both be reasonable choices; the difference lies in how each organises scope, coordination and continuity — and in how clearly each answers your questions before you travel.

  • A Mosaic Embryo Result: What to Discuss With Your Clinical Team

    A mosaic embryo result often arrives as a short line in a laboratory report and a much longer list of questions at home. The result describes what was seen in the cells that were sampled and analysed. It does not, by itself, tell you what to do next. That conversation belongs with the clinicians who know your history, your report and the laboratory that produced it.

    This guide is about preparing for that conversation well: what to bring, what to ask, and how to keep separate ideas that are easy to blur together. It is written for international patients who may be reading a report in a second language, at a distance from the clinic, or before a remote appointment.

    Start with the report, not the percentage

    The most common mistake is to treat a mosaic percentage as a universal threshold with a fixed meaning. Laboratories differ in how they define and report mosaicism, and a mosaic result has to be interpreted in the context of the laboratory that issued it. Professional guidance from ASRM makes this point directly: mosaic reporting categories and thresholds can differ between laboratories, and a mosaic result requires interpretation in the context of the reporting laboratory.

    That has a practical consequence for your appointment. Instead of asking only “is 30% bad?”, ask your team to walk you through how this laboratory defines and reports mosaicism, what its validated thresholds are, and what the report’s own wording says about confidence and limitations. The same number can carry different weight depending on the assay, the validation behind it and the way the result is expressed.

    It also helps to know what the test itself can and cannot do. PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations and can produce incorrect findings. A result does not guarantee a successful pregnancy or a healthy child. Your team should be able to explain where those limits sit for your specific report.

    Separate three different questions

    Mosaic conversations go sideways when three separate questions get merged. Ask your clinicians to address each one on its own:

    • What did the laboratory report? The reported mosaic percentage, the chromosome or chromosomes involved, whether the finding is full or segmental, and how the laboratory describes its own confidence.
    • What does that mean for the whole embryo? The biopsy samples a small number of cells. A result is an inference about the embryo from that sample, not a complete map of every cell. Ask how much uncertainty your team attaches to the finding.
    • What would it mean for a pregnancy? Any personal risk figure is a separate clinical discussion that depends on the chromosome involved, your history and other factors. Ask your team to explain what is and is not known for your situation, rather than borrowing a number from a general article.

    Keeping these apart makes the appointment more useful. You are not asking for one reassuring sentence; you are asking for a structured explanation you can understand and record.

    What to bring and what to request in writing

    Bring the full laboratory report, not a summary message. If you have had earlier cycles or testing, bring those reports too, because context across cycles can matter to the interpretation. Note the embryo identifiers exactly as they appear, so there is no confusion about which embryo is being discussed.

    A short records checklist for the appointment:

    • The complete PGT report, including any footnotes, thresholds or classification notes
    • Embryo identifiers and the day of biopsy or freezing, as recorded by the clinic
    • Prior PGT or IVF cycle reports, if any
    • Relevant genetic or medical history your team has asked about
    • Your written question list, in the order that matters most to you

    During or after the appointment, ask which points can be confirmed in writing, such as the laboratory’s reporting categories, the clinic’s general approach to mosaic embryos, and the next appointment or decision point. A written summary is easier to re-read calmly and to share with a partner or another clinician.

    Questions about transfer policy and follow-up

    If transfer of a mosaic embryo is being considered, the discussion should cover more than the percentage. Useful questions include:

    • How does this clinic describe its approach to mosaic embryos, and where is that policy written down?
    • Does the chromosome involved, or whether the finding is full or segmental, change how the team would discuss this embryo?
    • What alternatives would the team want you to understand before deciding, including waiting, further testing or another cycle?
    • If transfer goes ahead, what prenatal follow-up discussion would be offered, and who would lead it?
    • What would the team want to know from you before making a recommendation?

    These are clinical questions, and they belong with your treating clinicians. A coordination service can help you organise and send them, but it does not interpret results or recommend treatment.

    Preparing for a remote consultation

    Many international patients first discuss a mosaic result by video or phone. A little preparation makes that format work better. Send the full report and your question list ahead of time if the clinic allows, and confirm the appointment time in your own time zone. Ask whether an interpreter is available and whether the consultation can be recorded or summarised in writing.

    If you are comparing how different clinics handle mosaic results, it can help to read broadly first. A general guide to interpreting PGT-A results, including mosaic embryos, and an explanation of what embryo biopsy can and cannot reveal give useful background before you speak. For a closer look at how reports are structured, see how to read a PGT-A laboratory report.

    After the appointment: records and handover

    Before you leave Thailand, or before a remote consultation ends, agree how records will reach you and your home clinicians. Ask for the report, the consultation summary and any written policy you discussed. Confirm who will answer follow-up questions and by what method. If you are returning home, a clear handover plan avoids repeating the same conversation from scratch with a new team.

    If you would like help organising your question list, gathering records or arranging a remote consultation, you can request a case review. Coordination support can prepare and communicate; the clinical interpretation and any treatment recommendation remain with your licensed clinicians.

    Sources: Mosaic reporting categories and thresholds can differ between laboratories, and a mosaic result requires interpretation in the context of the reporting laboratory. — ASRM mosaic PGT-A committee opinion, 2023, Fertil Steril 120:973-982 (checked 2026-10-15).

  • What PGT Can and Cannot Tell You About Recurrent Pregnancy Loss

    Recurrent pregnancy loss is a frustrating diagnosis, and it is understandable to look for a test that promises an explanation. Preimplantation genetic testing (PGT) is often raised in that search. It deserves a clear answer about scope: PGT examines embryos created in an IVF cycle. It does not investigate why previous pregnancies were lost, and it does not treat the conditions that cause most losses.

    That does not make PGT irrelevant. It means the test answers a narrower question than many patients expect, and the value of that answer depends on what else has been assessed.

    What PGT actually examines

    PGT is an umbrella term for several tests performed on a small sample of cells taken from an embryo, usually at the blastocyst stage. Each type addresses a different question:

    • PGT-A looks at chromosome number in the sampled cells. It is used to identify embryos with an abnormal number of chromosomes, a finding called aneuploidy.
    • PGT-SR is designed for people who carry a known chromosomal structural rearrangement, such as a balanced translocation. It looks for the specific imbalance that rearrangement could pass on.
    • PGT-M is designed for a known single-gene (monogenic) condition that runs in a family.

    These are different tests with different purposes, and they are not interchangeable. The comparison of PGT-A, PGT-M and PGT-SR sets out how the questions differ. In a recurrent loss discussion, PGT-A is the type most often raised, because chromosome errors in the embryo are a recognised contributor to early miscarriage. PGT-SR only becomes relevant if a structural rearrangement has actually been found in one partner, and PGT-M only if a specific monogenic condition has been identified.

    Why a normal PGT-A result does not close the investigation

    PGT-A screens the embryo. It does not examine the uterus, the endocrine system, the immune system, blood clotting, parental chromosomes, or the many other factors that clinical assessment of recurrent loss considers. A couple can have embryos that test as having the expected chromosome number and still experience a miscarriage, because the cause in that pregnancy lay outside the embryo’s chromosome count.

    This is the central limit. PGT-A can reduce the chance that an embryo with an abnormal chromosome number is selected for transfer. It cannot lower the risk that comes from non-chromosomal factors, and it cannot tell you why earlier losses happened. A result from an embryo biopsy is not a diagnosis of the couple, and it is not a substitute for the standard workup of recurrent loss, which may include parental karyotyping, imaging of the uterus, and other investigations your clinician considers appropriate.

    Where the evidence itself has limits

    Even within its own scope, PGT-A is not a certainty machine. Several technical and interpretive limits matter when you are weighing it:

    • Sampling. The test reads cells from a biopsy, not the whole embryo. A sampled result does not establish the cell composition of the entire embryo.
    • Mosaic results. Sometimes the laboratory reports an intermediate chromosome finding, described as mosaicism. This is inferred from the biopsy findings, and technical factors can contribute to such results. What a mosaic result means for a particular embryo should be discussed with the treating clinician and a genetic counsellor.
    • Incorrect or inconclusive findings. PGT-A can produce results that do not reflect the embryo accurately, and some samples do not yield a usable answer.
    • Biopsy itself. Removing cells from an embryo carries a risk of damage that can affect further development.
    • No guarantee. A PGT result does not guarantee a successful pregnancy or a healthy child.

    These points come from regulator and professional-society patient information, and they are general. They are not a prediction about your embryos or your chances. The guide to what PGT-A screens and who it may help covers the test’s purpose in more detail.

    Separating the embryo factor from other factors

    A useful consultation does not ask “should we do PGT?” in isolation. It asks your clinician to separate two questions: what role, if any, embryo chromosome problems may have played in your losses, and what other factors have been assessed or still need assessment. Those are different lines of enquiry, and only the second can address causes such as uterine, endocrine, immune or clotting-related conditions.

    You can ask directly:

    • Which investigations have already been done for our losses, and which are still outstanding?
    • Has parental karyotyping been performed, and does it change whether PGT-SR or PGT-M is relevant for us?
    • If we use PGT-A, what would a normal result change in our plan, and what would it not change?
    • How would a mosaic or inconclusive result be handled in our case?
    • What alternatives exist if we decide against embryo testing?

    These are clinical questions, and they belong with a licensed clinician who can see your history. A coordination service can help you organise the conversation and the records, but it does not interpret results or advise on treatment.

    Records worth bringing to a PGT conversation

    Recurrent loss discussions go better when the history is documented rather than recalled. A practical record set includes:

    • A dated list of previous pregnancies and losses, with gestational age where known.
    • Any prior loss workup: blood tests, imaging, uterine assessment, and pathology reports if tissue was examined.
    • Parental karyotype results, if performed.
    • Any genetic counselling letters or reports of a known familial condition.
    • Current medication list and relevant past medical history.

    Approximate dates are fine if exact ones are not available; write down what you know and mark what is uncertain. Do not stop or change any medication in preparation for a consultation unless your prescribing clinician tells you to.

    Planning the conversation, including from abroad

    If you are considering treatment in Thailand, the practical work starts before any appointment. A short written summary of your history, a question list, and a clear note of which records are still missing will make a remote consultation more useful. It also helps to ask, in writing, what the hospital needs from you, in what format, and whether a remote discussion is possible before travel.

    For patients comparing options, it can help to read broadly about how PGT is discussed for recurrent loss in Thailand, for example this cautious guide to PGT and recurrent miscarriage, and to keep provider shortlists as a separate research task rather than a substitute for clinical assessment. If you want a starting point for that separate comparison, the countrywide shortlist of IVF hospitals and clinics is an editorial overview, not evidence that any provider produces better outcomes.

    Thailand PGT can help organise records, prepare a question list, request appointments or remote consultations, and coordinate follow-up communication after you return home. Scope and any fees are confirmed individually, and clinical decisions remain with your treating clinicians.

    Frequently asked questions

    Does PGT-A prevent miscarriage?

    No. PGT-A screens embryos for chromosome number, so it can reduce the transfer of embryos with an abnormal count. It does not prevent miscarriage caused by factors outside the embryo's chromosomes, and it cannot guarantee a pregnancy or a healthy child.

    Should everyone with recurrent pregnancy loss have PGT?

    There is no single answer that applies to everyone. Whether PGT is appropriate depends on your history, what investigations have already been done, and what you and your clinician are trying to learn. It is not a replacement for the standard assessment of recurrent loss.

  • When PGT Leaves No Embryo for Transfer: What to Ask Your Clinician

    A cycle can end with no embryo available for transfer even when stimulation, retrieval and fertilisation appeared to go to plan. When PGT is part of the cycle, the news often arrives as a short message or a report with numbers and classifications that are hard to interpret on your own. The most useful next step is usually a scheduled conversation with the clinician who knows your cycle, armed with specific questions about the report and about what the result does and does not tell you.

    This guide is about preparing that conversation. It does not interpret your result or recommend a treatment. Those decisions belong to your treating clinician and, where relevant, a genetic counsellor.

    Start with the report itself

    Before the appointment, ask for the full written laboratory report, not only a summary message. Read it alongside these questions:

    • How many embryos were biopsied? The number tested is the denominator for everything else. A result based on one or two embryos carries different weight from one based on several.
    • What happened to each embryo? Ask for a line-by-line explanation: which embryos were reported as having an abnormal chromosome number, which were reported as mosaic, which gave no result or an inconclusive result, and which were not tested at all.
    • Was any embryo left untested or still in culture? Sometimes an embryo did not reach the biopsy stage, or a decision was made not to test one. Confirm whether anything remains frozen or under observation.
    • What do the laboratory’s own categories mean? Thresholds and reporting categories are laboratory-specific. Ask the clinician to explain the terms used in your report rather than relying on general definitions you have read online.

    PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations: it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A). That matters here: a report of no transferable embryo is a statement about the sampled cells and the laboratory’s classification, not a complete account of every embryo’s potential.

    If your report uses the word mosaic, ask what it meant in your case. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo (ASRM: mosaic PGT-A results). The clinician and genetic counsellor should explain what this means for your situation and what uncertainty remains.

    If your testing was PGT-M or PGT-SR rather than PGT-A, the questions shift. PGT-M concerns a known monogenic condition, PGT-SR concerns chromosomal structural rearrangements, and the two address different questions; the treating team and a genetic counsellor should discuss the relevant history, test design and suitability (HFEA: PGT-M and PGT-SR). Ask whether the outcome reflects the condition the test was designed to detect, a technical limitation of the test, or something else.

    Ask why, in stages

    “Why did this happen?” is really several questions. Work through them in order, because the answer at each stage shapes what is worth discussing next.

    1. Stimulation and retrieval. How many eggs were retrieved, how many were mature, and how does that compare with what your clinician expected for your profile?
    2. Fertilisation. How many eggs fertilised, and which fertilisation method was used? Ask whether the method is being reconsidered and on what basis.
    3. Development to biopsy stage. How many embryos reached the stage needed for testing? Embryo development can arrest before testing, which is a different problem from a tested embryo being classified as unsuitable.
    4. The test result itself. Of those tested, how many were classified in each category, and does the pattern suggest a biological factor, a laboratory or technical factor, or chance?
    5. What remains uncertain. Ask directly: is there anything in this cycle that you would investigate further before another attempt?

    Factors such as maternal age, sperm factors and previous cycle history may be relevant, but only your clinician can weigh them for you. Ask which factors they consider most important in your case and why.

    Discuss individual options, not a menu

    There is no standard next step after a cycle with no transferable embryo. The options your clinician raises may include repeating a cycle with changes to stimulation or laboratory approach, further investigations, considering donor gametes or embryos where lawful and available, pausing treatment, or stopping. Each carries different medical, practical and emotional implications.

    Useful questions include:

    • What would you change in another cycle, and what evidence supports that change?
    • What would you expect to be different, and what would remain uncertain?
    • Are there investigations you would recommend before another cycle?
    • What are the alternatives if another cycle is not something we want to pursue now?
    • What is the realistic timeline for deciding, and does waiting affect anything?

    Ask for the reasoning behind any recommendation, including its limits. A clinician should be able to explain why an option is being suggested for you specifically, not only in general.

    Plan the conversation and the follow-up

    If you are arranging care from abroad, a remote consultation may be the practical way to have this discussion. Before booking, confirm the format, who will attend, whether a genetic counsellor will be included, and what records the clinician wants in advance. Sending the full laboratory report, cycle summary and any previous treatment records ahead of time makes the conversation more productive.

    During the appointment, take notes or ask permission to record. Ask for the clinician’s written summary afterwards, and confirm what has been added to your file. If you want a second opinion, request copies of the laboratory report, embryology records and cycle medication history in a format you can share.

    Practical support can sit alongside the clinical conversation without replacing it. A coordination service can help organise your questions and records before the appointment, request documents from the hospital, and arrange remote consultation times. It does not interpret results or advise on treatment. If you are weighing where to continue care, background reading on how to read a PGT-A report from a Thai laboratory and on what PGT testing can and cannot change about success rates may help you frame questions, and a guide to the fertility doctor’s role during a PGT IVF cycle can clarify who is responsible for what.

    If you are considering another cycle in Thailand, it is also reasonable to ask how a future frozen transfer would be planned; the parts of a frozen embryo transfer plan to confirm with your doctor lists the practical points. And if you return home before deciding, follow-up after returning home explains how to keep records and questions moving between countries.

    Look after the practical and emotional side

    Give yourself time before making a decision. Ask whether the clinic offers counselling or a follow-up appointment specifically to discuss the cycle, and whether a genetic counsellor is available. Write down what you understood and check it at the start of the next conversation. If you feel pressure to decide quickly, say so and ask what genuinely needs to be decided now versus later.

    One cycle’s result is information, not a verdict. The purpose of the conversation is to understand what the report shows, what remains unknown, and which choices are yours to make with clinical guidance.

    Frequently asked questions

    Does a report of no embryo for transfer mean another cycle will have the same result?

    Not necessarily. The outcome of one cycle reflects that cycle's eggs, sperm, embryo development and testing results. Your clinician can explain which factors are likely to recur and which might change with a different approach, but no one can predict a future cycle's result.

    Can I ask for the laboratory report even if the clinic has already explained the result?

    Yes. Asking for the full written laboratory report is reasonable and helps you prepare specific questions. A coordination service can help request the document from the hospital; interpretation remains with your treating clinician and genetic counsellor.

  • Which Stages Shape When a PGT Report Becomes Available?

    A PGT report does not appear at a single moment. It is the end point of a chain that begins on the day an embryo is biopsied and passes through sample handling, laboratory analysis and clinical review before anyone can read a result. If you are trying to plan around a report date, it helps to know where the time actually goes, which parts are controlled by the genetics laboratory, and which parts depend on your clinic’s own schedule.

    This guide explains the stages in order. It does not give turnaround times, because those depend on the specific laboratory, the test type and the workload at the time. Instead, it shows you what to ask so that an expected date is based on your own case rather than a general impression.

    Stage 1: Embryo culture and the day of biopsy

    The clock starts when a sample is taken, not when the cycle begins. In a typical PGT cycle, embryos are cultured for several days and a small number of cells is removed from the trophectoderm, the outer layer that will form the placenta, at the blastocyst stage. The embryo biopsy process and timing matter here for a simple reason: an embryo biopsied on day five and one biopsied on day six do not enter the laboratory queue on the same date.

    This stage is largely clinic-controlled. It depends on how the embryos develop, which day the embryology team judges biopsy appropriate, and the laboratory’s own working days. If a cycle produces embryos that reach blastocyst on different days, samples may reach the genetics laboratory in more than one batch. That is one reason a single “report date” can be harder to pin down than patients expect.

    It is worth knowing how your clinic labels blastocysts, because the day number in a report often traces back to this stage. The guide to day-five, day-six and day-seven blastocyst labels explains what those numbers mean.

    Stage 2: Sample handling, labelling and transport

    Once cells are removed, they become a specimen that must be identified, prepared and moved to the genetics laboratory. Sample processing at this point is about custody and traceability as much as biology: correct labelling, the right container, and a documented handover. If the genetics laboratory is on the same site as the IVF laboratory, transport is short. If it is elsewhere, the sample has to travel under agreed conditions.

    This is a stage where small administrative problems can add delay. A mislabelled tube, an incomplete request form or a missing clinical detail may need to be resolved before analysis can begin. You will not see this happen, but it is one reason a clinic may ask for information about your history before the laboratory starts work.

    Stage 3: DNA amplification and library preparation

    The biopsy sample contains very little DNA, so the laboratory must amplify it before analysis. This preparation step is technical and largely invisible to patients, but it is a genuine part of the timeline. The sample has to be processed to a point where the chosen testing method can read it reliably.

    For PGT-A, which assesses chromosome number, the laboratory prepares the sample for a genome-wide analysis. For PGT-M, which looks at a known monogenic condition, and PGT-SR, which looks at chromosomal structural rearrangements, the test is designed around a specific family situation. The HFEA’s information on PGT-M and PGT-SR explains that these tests address different questions and require discussion of the relevant history and test design with a treating team and genetic counsellor.

    That test design is the main reason PGT-M often takes longer than PGT-A. A PGT-M test may need to be built and validated around your family’s specific genetic variant, sometimes using samples from relatives, before an embryo sample can be interpreted. This preparatory work can happen before or alongside an IVF cycle, but it is a separate task from analysing the biopsy itself. PGT-SR also involves test-specific design, though the details vary by rearrangement.

    Stage 4: Sequencing or other analysis

    With the sample prepared, the laboratory runs its analysis. Different methods suit different questions: PGT-A is commonly analysed with next-generation sequencing, while PGT-M may use PCR-based or sequencing approaches depending on the design. The method affects how the data are generated and how much interpretation is needed afterwards, but the laboratory, not the patient, decides which is appropriate.

    This is the stage most people picture when they think about laboratory turnaround. It is also the stage where batching matters. Laboratories often run samples in groups rather than one at a time, so the date your sample enters the run can matter as much as the length of the run itself.

    Stage 5: Bioinformatics analysis and quality review

    Raw data are not a report. The laboratory has to analyse the output, check that the sample met quality thresholds, and decide whether the result is clear enough to report. Some samples need repeat analysis or are reported with caveats. The HFEA’s PGT-A information notes that testing has limitations and can produce incorrect findings, which is part of why this review step exists.

    Quality review is also where nuanced findings are handled. A mosaic PGT-A result, for example, is inferred from intermediate chromosome copy-number findings in a biopsy sample, and technical factors can contribute to such findings. The ASRM committee opinion on mosaic PGT-A results makes clear that a sampled result does not establish the cell composition of the whole embryo. Reports that include this kind of finding may take longer to finalise because the wording and interpretation need care. The guide to understanding PGT-A results and mosaicism covers how to read such reports.

    Stage 6: Clinical scientist sign-off and report release

    Before a report reaches you, it is reviewed and signed off by the laboratory’s clinical team. This is a professional checkpoint, not a formality. The report then has to be released to your clinic through whatever channel has been agreed.

    This stage is where clinic and laboratory responsibilities meet. The laboratory controls the analysis and sign-off; your clinic controls how and when the result is communicated to you. A report may be finalised on a date when your treating clinician is not immediately available to discuss it, and some clinics prefer to schedule a conversation rather than send a result without context.

    Stage 7: How the result reaches you

    Ask in advance how results will be shared: a portal, a scheduled call, an email with a follow-up appointment, or a conversation at your next visit. Ask who will explain the report and whether a genetic counsellor is involved. For PGT-M and PGT-SR, discussion with a genetic counsellor is part of interpreting what the result does and does not mean.

    If you are planning to travel home after the cycle, this stage deserves early attention. A result that arrives after you leave may need a remote conversation, and any records you want for your home clinic should be requested explicitly. The guide to checking for missing records before an IVF clinic handover is a useful prompt for that conversation.

    Which stages are laboratory-controlled and which are clinic-controlled

    Stage Mainly controlled by What you can reasonably ask about
    Embryo culture and biopsy day IVF clinic and embryology team Which day biopsy is planned and whether samples are batched
    Sample handling and transport IVF laboratory and genetics laboratory Where the genetics laboratory is and how samples are transferred
    Amplification and test design Genetics laboratory Whether test design is already complete for PGT-M or PGT-SR
    Analysis run Genetics laboratory How often runs are scheduled
    Bioinformatics and quality review Genetics laboratory What happens if a sample needs repeat analysis
    Sign-off and release Genetics laboratory, then your clinic Who releases the report and to whom
    Communication to you Your clinic Format, timing and who will explain the result

    How to get a realistic expected date

    Rather than asking “how long does PGT take?”, ask for a date range tied to your own cycle and test type. A useful request sounds like this: “For our situation, with biopsy planned around this date and this test type, what is the expected window for a signed report, and what could move it?” Then ask for a named point of contact for follow-up and the clinic’s process if the window passes without a result.

    It also helps to separate the two clocks. The laboratory clock starts when a suitable sample arrives. The clinic clock includes scheduling, communication and any conversation needed to explain the result. A report can be ready while the discussion is still being arranged, and that gap is worth planning for, especially if you have travel dates.

    Finally, keep a simple record of dates: biopsy day, the date you were told the sample was sent, the expected window, and any follow-up you have requested. If you are comparing clinics or preparing questions, the PGT laboratory quality questions for Thai IVF clinics can help you frame them. A coordinator can help organise these questions and request documents, but the clinical interpretation of your report belongs with your treating clinician and, where relevant, a genetic counsellor.

    Frequently asked questions

    Does a day-six biopsy always mean a later report than a day-five biopsy?

    Not necessarily, but it can shift the start date. A sample taken later enters the laboratory queue later, and if samples are batched, the difference may be absorbed or may add time. Ask your clinic how it handles samples from different biopsy days.

    Why might a PGT-M report take longer than a PGT-A report?

    PGT-M is designed around a specific monogenic condition and may require test development and validation before an embryo sample can be interpreted. PGT-A assesses chromosome number across the genome and does not usually need that family-specific design step. The exact difference depends on the laboratory and whether test design is already complete.

  • Low Egg Yield or Few Mature Eggs in One Cycle: What to Review Before Treatment in Thailand

    A cycle that produced few eggs, or few mature eggs, is disappointing, but it is also one of the most informative events in fertility care. One retrieval gives your clinicians a set of measurements they did not have before: how your ovaries responded to a particular protocol and dose, how many follicles developed, how many eggs were collected, how many of those were mature, and what happened afterwards.

    The useful question before planning treatment in Thailand is therefore not “what went wrong?” but “what does this cycle tell us, and what would we change or test next?” This guide sets out how to organise that review so a consultation starts with evidence rather than starting from scratch.

    First, separate two different problems

    Patients often describe a low-yield cycle as “poor response”, but two distinct situations sit under that phrase, and they lead to different review questions.

    • Poor ovarian response describes a cycle in which few follicles developed and few eggs were retrieved. The review focuses on ovarian reserve markers, the stimulation protocol and starting dose, how the dose was adjusted, and whether the trigger was timed well.
    • Low mature-oocyte yield describes a cycle in which a reasonable number of eggs was retrieved, but a small proportion of them were mature. The review focuses on trigger type and timing, the interval between trigger and retrieval, and how maturity was assessed in the laboratory.

    The two can occur together, and both can occur alongside poor fertilisation or poor embryo development. Before a consultation, write down which description fits your cycle, using the numbers in your report rather than your memory of how it felt. If you are unsure, bring both sets of numbers and let the clinician characterise the cycle.

    The records that make a review possible

    A Thai clinic reviewing a cycle performed elsewhere needs the raw data, not only a summary letter. Ask the treating clinic for a full cycle report and, where available, the laboratory record. The items below are the ones that most directly inform a discussion about stimulation and maturation strategy.

    Record Why it matters for the review
    Stimulation protocol name, starting dose and any dose changes with dates Shows what was already tried and how the ovaries responded to it
    Ovarian reserve markers measured before the cycle (for example AMH and antral follicle count, if done) Provides context for whether the response was expected
    Follicle counts and sizes on trigger day Links the number of developing follicles to the number of eggs retrieved
    Estradiol trend across stimulation Helps interpret follicular growth and the decision to trigger
    Trigger medication, dose and exact time; retrieval time Central to any question about maturation timing
    Eggs retrieved, mature (MII) eggs, and maturation rate Distinguishes a response problem from a maturation problem
    Fertilisation method and results; embryo numbers and stages reached Shows whether the difficulty continued after retrieval
    Any genetic testing performed on embryos and its outcome Relevant if testing was part of the previous plan

    Two practical points. First, ask for records with dates and units, because dose and timing questions cannot be answered from a narrative summary. Second, keep your own plain-language timeline of the cycle — start of stimulation, trigger, retrieval, transfer or freeze — since clinics sometimes hold fragments of the file in different departments.

    Questions worth putting to the clinician

    These are clinical questions, and they belong with the treating doctor or a fertility specialist, not with a coordination service. A useful consultation covers them in roughly this order.

    1. How would you characterise the last cycle? Was this a response issue, a maturation issue, both, or something else in the laboratory pathway?
    2. What would you keep and what would you change? Ask specifically about protocol family and starting dose, and about whether a different trigger approach or trigger-to-retrieval interval would be considered.
    3. How is maturity assessed in your laboratory? Maturity is judged from the appearance of the egg at collection; ask how that assessment is done and recorded.
    4. Is a repeat cycle with adjustment reasonable, or is a different strategy worth discussing? This may include further investigation before another stimulation, or a conversation about what is realistic given your history.
    5. What would you want to see in the next cycle to judge whether the change worked? Agreeing in advance what counts as progress prevents another cycle being judged only by its final outcome.
    6. What can and cannot be predicted? No clinician can promise a specific egg number, maturity rate, embryo count or pregnancy outcome before assessment, and any plan should be described in terms of possibilities rather than guarantees.

    If embryo testing is part of the discussion, keep the purpose clear. PGT-A examines chromosome number in cells sampled from an embryo; it has limitations and can produce incorrect findings, and whether to use it should be discussed for the individual situation rather than assumed. A PGT-A result does not guarantee a successful pregnancy or a healthy child (HFEA). Where a reported finding is intermediate or mosaic, that is a sample-based inference rather than a description of the whole embryo, and technical factors can contribute to it (ASRM). PGT-M and PGT-SR address different questions again — a known monogenic condition and a chromosomal structural rearrangement respectively — and suitability is a matter for the treating team and a genetic counsellor (HFEA).

    What a low-yield cycle does not tell you

    It is tempting to read a single cycle as a fixed prognosis. It is better read as one observation under one set of conditions. A protocol change, a different trigger decision or a different starting dose may produce a different picture — or may not. What cannot be promised before a clinician reviews your records is any particular egg count, maturation rate, embryo number or chance of pregnancy.

    This is also why comparing clinics by headline figures is a weak substitute for a case review. If you do want to research provider options, treat any shortlist as a starting point for questions about how a clinic would approach your specific history, not as evidence about your likely outcome. A countrywide overview of IVF hospital and clinic options in Thailand can help you organise that research.

    Planning the practical side from abroad

    Once the clinical questions are clear, the logistics become manageable. Three areas usually need attention before travel.

    Getting a useful remote consultation

    Ask what format the consultation takes, which records the clinic wants in advance and in what language, whether there is a fee, and who will review the file before the appointment. Sending records ahead is what makes a first conversation substantive rather than introductory. If you use a coordination service, its role is to organise records and relay questions and appointment arrangements; interpretation of results and any treatment recommendation remain with the clinicians.

    Timing and travel dependencies

    Stimulation and retrieval are tied to your cycle dates, so travel planning depends on a schedule the clinic confirms. Before booking anything, clarify the expected length of stay, which appointments must be in person, and what happens if dates shift. General guidance on planning an IVF timeline in Thailand can help you map those dependencies, and a review of stimulation protocol options will make the protocol conversation easier to follow.

    Records to bring home

    Whatever the outcome, ask before you leave how you will receive the cycle record, who will send it, and in what format. A complete record of the next cycle is what makes the following review possible — and if you are considering further treatment elsewhere, it is the document that travels with you.

    A worked example of the review

    Consider a hypothetical patient whose report shows a standard antagonist protocol, nine follicles above 14 mm on trigger day, seven eggs retrieved, two mature, one fertilised, no blastocyst. Her review has two layers. The retrieval-to-follicle ratio suggests the response itself was not the main issue; the low mature count and the drop-off afterwards are where the questions concentrate. She would ask about trigger timing and type, how maturity was assessed, and whether anything in the laboratory pathway explains the fertilisation result. She would also ask what the team would monitor differently next time. She would not ask a coordinator to interpret the numbers, and she would not expect a promise of a better result.

    That is the shape of a good pre-treatment review: specific records, specific questions, and a clear line between what the clinician decides and what you can prepare.

    Frequently asked questions

    Can a clinic in Thailand tell me in advance how many eggs I will produce next cycle?

    No. Egg numbers depend on your response to a specific protocol and cannot be guaranteed before assessment. A clinician can review your previous cycle records, explain what they would adjust and what they would monitor, and describe possibilities rather than promise a count.

    Should I repeat the same protocol if the first cycle produced few eggs?

    That is a clinical decision for the treating specialist after reviewing your protocol, doses, trigger timing and laboratory results. Some histories support adjusting the existing approach; others prompt a different discussion. Bring the full record so the decision is based on data rather than on the outcome alone.